Zevra Therapeutics Stock Down — European Panel Slams Arimoclomol Bid for Niemann-Pick Type C
The CHMP issues a negative opinion on Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C, prompting a re-examination request.
A European health group said no to Zevra's medicine for a rare disease, so the company has to try again to prove it works. This is a setback, but you can watch if they fix the problems and reapply—that will tell you if the company can bounce back.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.